Fig. 5. (a) Schematic of the AIEgen-based biomimetic nano-cancer stem cell scavenger. (b) Surviving situation of 4T1 CSC cells treated with different formulations: (A) γ-H2AX-stained CSCs treated with different formulations, (B) corresponding γ-H2AX fluorescence intensity after different treatments, (C) surviving fraction of 4T1 CSC cells treated with different formulations, (D) surviving fraction of 4T1 CSC cells treated with different concentrations, and (E) proposed mechanism for combined mild PTT/aspirin based on the TAFL system. Reproduced with permission from ref. 72. Copyright 2024, Wiley-VCH Verlag.
